مواقع التدريسيينجامعة الكوفة
Ali Neamah Wannas Alwaeli
Assistant Professor

Ali Neamah Wannas Alwaeli

0Publications
0Lectures
0Interests

About

Academic and Scientific Biography

Name: Ali Neamah Wannas Al-Waeli
Academic Rank: Assistant Professor
Specialization: Pharmaceutics
Affiliation: Department of Pharmaceutics and Pharmaceutical Industry, Faculty of Pharmacy, University of Kufa

Education

- Bachelor of Pharmacy (B.Pharm.), College of Pharmacy, University of Kufa, 2012.
- Master’s Degree in Pharmacy, College of Pharmacy, Mustansiriyah University, 2020.
- Ph.D. in Pharmacy, College of Pharmacy, Mustansiriyah University, 2025.

Academic Career

- Teaching Assistant, Department of Pharmaceutics and Pharmaceutical Industry, College of Pharmacy, University of Kufa, 2014–2017.
- Assistant Lecture, Department of Pharmaceutics and Pharmaceutical Industry, since 2020.
- Lecturer, Department of Pharmaceutics and Pharmaceutical Industry, since 2023.
- Assistant Professor**, Department of Pharmaceutics and Pharmaceutical Industry, since 2026.

Research Interests

Research interests focus on pharmaceutics and pharmaceutical technology, particularly the design and development of advanced drug delivery systems, applications of nanotechnology in pharmaceutical formulations, improvement of the solubility and bioavailability of poorly water-soluble drugs, development of targeted drug delivery systems, and the design and evaluation of both conventional and advanced pharmaceutical dosage forms.

Main research interests include:

- Nanoparticulate drug delivery systems.
- Nanostructured lipid carriers.
- Self-emulsifying and self-nanoemulsifying drug delivery systems.
- Formulation development for poorly water-soluble drugs.
- Buccal and transmucosal drug delivery systems.
- Development and evaluation of pharmaceutical formulations.
- Targeted drug delivery for cancer therapy.
- Quality control and in vitro evaluation of pharmaceutical products.

Research Activities

Published a number of research articles in the fields of pharmaceutics, pharmaceutical technology, and drug delivery systems. Selected publications include:

- Design, Optimization and Characterization of Mucoadhesive Buccal Film as a Novel Delivery System for Doxazosin Mesylate, published in Saudi Pharmaceutical Journal, 2026.

- Unraveling the Role of Hyaluronic Acid on the Targeting of Vinorelbine-Loaded NLC for Lung Cancer, published in Pharmacia, 2025.

- Comparative In Vitro Evaluation of Marketed Antacids and Natural Remedies in Iraq, published in 2026.

- Preparation and In Vitro Evaluation of Self-Nano Emulsifying Drug Delivery Systems of Ketoprofen, published in International Journal of Applied Pharmaceutics.

- Characterization and Optimization of Oral Solid Supersaturable Self-Emulsifying Drug Delivery System of Cilostazol.

- Preparation and In-Vitro Evaluation of Cilostazol Self-Emulsifying Drug Delivery System.

- Quality Control Testing of Conventional Clopidogrel Bisulfate Tablets Marketed in Iraq.

Teaching Activities

Involved in teaching courses related to pharmaceutics and pharmaceutical industry for undergraduate pharmacy students, in addition to contributing to postgraduate teaching, supervision, and participation in scientific and academic committees and activities.

Researcher Identifiers and Academic Profiles

ORCID: 0000-0002-1563-7026

Research Interests

1

Publications

2
2025

Unraveling the role of hyaluronic acid on the targeting of vinorelbine-loaded NLC for lung cancer

AuthorsAli Wannas, Monther F. Mahdi and Nidhal Khazaal Maraie
JournalPharmacia
Date2025-03-12
Abstract

Hyaluronic acid (HA) is a naturally occurring mucopolysaccharide that interacts specifically with overexpressed receptors on cancer cells,such as CD44, RHAMM, and LYVE-1, enabling targeted drug delivery to tumors. The present work aims to prepare an activated nanolipidcarrier (NLC) using HA as a ligand to enhance the selectivity and safety of parenterally administered vinorelbine (Vn). The preparationmethod included the chemical conjugation of pegylated-DSPE with HA, followed by the loading of Vn using ultrasonication-homoge-nization to prepare activated HA-NLC (Vn-loaded HA-NLC). In vitro evaluation for the prepared formulation had a mean particle sizeof 102 nm, a zeta potential of -44.1 mV, and gave a drug release of 85.23% within 48 hours with an IC50 of 35.7 μg/mL against the lungcancer cell line A549 in comparison to the marketed drug and non-activated Vn-loaded NLC, which gave IC50 values of 45.65 μg/mL and57.29 μg/mL, respectively. The in vivo study in mice of the Kunming strain included the induction of lung cancer (LL2) xenograft (equiv-alent to humanized A549), measurement of mice body weight and tumor volume, histopathological study for 4 weeks, and MRI follow-upscan of tumor tissue for 24 hours using SPION as a contrast agent. The result showed a significant (P < 0.05) increase in body weight, exten-sive tumor apoptosis, smaller tumor size, and better accumulation inside tumor tissue for mice treated with activated HA-NLC comparedto non-activated NLC and marketed products. It was concluded that HA-NLC promoted the selective targeting and accumulation of Vn in-side tumor tissue, prolonging the retention duration and enhancing the drug’s cytotoxic effect with increased mice weight as a sign of safety.

2020

التحضير والتقييم المختبري لنظام ايصال دواء السيلوستازول بشكل سائل ذاتي الاستحلاب

Authorsعلي نعمه وناس،, نضال خزعل مرعي
JournalAl-Mustansiriyah Journal of Pharmaceutical Sciences (AJPS),2020, Vol. 20, No. 1
Date2020-03-01
Abstract

الخلاصة: هذه هي المرة الأولى التي يتم فيها تحضير نظام إيصال الدواء المستحلب الذاتي النانوي (SEDD) من سيلوستازول باستخدام زيت الأوليك اسد ، و توين 80 كمضاد للشد السطحي و ترانسكيوتول كمساعد مضاد للشد السطحي. سيلوستازول هو مركب قليل الذوبان بالماء مثبط فسفوديستريز III والذي له تأثير مضاد للصفائح الدموية ومضخم للأوعية يستخدم لتخفيف أعراض العرج المتقطع. تم تحديد قابلية ذوبان سيلوستازول في مختلف الزيوت ، مضادات الشد السطحي ،ومساعدات مضادات الشد السطحي، وتم تعيين المستحلب النانوي باستخدام مخطط ثلاثي الحاله بنسب مختلفه من الزيت و مضادات الشد السطحي ، ومساعدات مضادات الشد السطحي تمت مقارنة قابليه تحرر الدواء مختبريا بين الصيفه (SEDD) المثاليه LT1 واللتي تحتوي علي زيت اوليك اسد ( 10% ) و توين 80 كمضاد للشد السطح ي ( 45% ) و ترانسكيوتول كمساعد مضاد للشد السطحي( 45% ) مع حب السيلوستازول المتوفر تجاربا. كانت الصيغة LT1 مقاومه للتخفيف ، مستقرة بالديناميكا الحرارية مع جهد زيتا من - 30.48 مللي فولت وحجم القطرة 154 نانومتر. أظهر قابليه تحرر الدواء مختبريا تفوق (LT1 (100% تحرير دواء مقارنة ب (64%) تحرر دواء في حب السيلوستازول المتوفر تجاربا

Lectures

7
View details